{"id":573335,"date":"2026-08-03T13:01:09","date_gmt":"2026-08-03T13:01:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/573335\/"},"modified":"2026-08-03T13:01:09","modified_gmt":"2026-08-03T13:01:09","slug":"integrating-majestec-9-data-into-treatment-decisions-for-relapsed-refractory-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/573335\/","title":{"rendered":"Integrating MajesTEC-9 Data Into Treatment Decisions for Relapsed\/Refractory Multiple Myeloma"},"content":{"rendered":"\n<p class=\"\">Building on the first patient case, Dr. Binod Dhakal and Dr. Prerna Mewawalla discuss how recently presented MajesTEC-9 data may influence treatment selection for patients with relapsed\/refractory multiple myeloma (RRMM) who experience an early relapse following frontline therapy.<\/p>\n<p class=\"\">Dr. Mewawalla explains how remission duration, disease biology, patient age, and anti-CD38 treatment history factor into her interpretation of the available evidence and subsequent treatment recommendations.<\/p>\n<p class=\"\">While acknowledging the promising outcomes observed with BCMA-directed bispecific antibodies, she notes that a relatively early relapse following transplant may indicate more aggressive disease biology and supports consideration of CAR T-cell therapy for eligible patients.<\/p>\n<p class=\"\">The discussion also explores how anti-CD38 exposure versus true anti-CD38 refractoriness may influence the selection of combination versus monotherapy approaches.<\/p>\n<p class=\"\">Ultimately, the segment highlights the importance of integrating emerging clinical trial data with patient-specific factors and shared decision-making when developing individualized treatment strategies for RRMM.<\/p>\n","protected":false},"excerpt":{"rendered":"Building on the first patient case, Dr. Binod Dhakal and Dr. Prerna Mewawalla discuss how recently presented MajesTEC-9&hellip;\n","protected":false},"author":2,"featured_media":527899,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[114,85,46],"class_list":["post-573335","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-business","tag-il","tag-israel"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/573335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=573335"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/573335\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/527899"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=573335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=573335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=573335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}